High Response Rate to Pembrolizumab in Unresectable Desmoplastic Melanoma Trial miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in a recent clinical trial. These results from the S1512 trial are being delivered in an oral presentation at the clinical trials plenary session of the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, on April 16th.
Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Published 14 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a Best of Journals: Renal Cell Carcinoma Session with Dr. Saby George from the Roswell Park Cancer Institute presenting impactful papers from the medical oncology perspective.
The first paper discussed by Dr. George was Motzer et al. s “Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial” was published in
Cancer.
1 CheckMate 025 previously showed superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma along with improved safety and tolerability.